137 related articles for article (PubMed ID: 34476821)
1. The long-term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008-2018).
Nolde M; Ahn N; Dreischulte T; Rückert-Eheberg IM; Güntner F; Günter A; Gerlach R; Tauscher M; Amann U; Linseisen J; Meisinger C; Baumeister SE
Aliment Pharmacol Ther; 2021 Oct; 54(8):1033-1040. PubMed ID: 34476821
[TBL] [Abstract][Full Text] [Related]
2. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction.
Sehested TSG; Gerds TA; Fosbøl EL; Hansen PW; Charlot MG; Carlson N; Hlatky MA; Torp-Pedersen C; Gislason GH
J Intern Med; 2018 Mar; 283(3):268-281. PubMed ID: 29024109
[TBL] [Abstract][Full Text] [Related]
3. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
4. Proton Pump Inhibitor Use and the Risk of Cardiovascular Complications and Death in Older Adults with Diabetes: A Population-Based Cohort Study.
Foresta A; Fernandez LO; Torrigiani G; Schena S; Roncaglioni MC; Nobili A; Tettamanti M; Franchi C; Fortino I; Succurro E; Sesti G; Baviera M
Drugs Aging; 2024 Mar; 41(3):239-249. PubMed ID: 38367169
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitor use represents an independent risk factor for myocardial infarction.
Shih CJ; Chen YT; Ou SM; Li SY; Chen TJ; Wang SJ
Int J Cardiol; 2014 Nov; 177(1):292-7. PubMed ID: 25499395
[TBL] [Abstract][Full Text] [Related]
6. Time-Varying Use of Proton Pump Inhibitors and Cognitive Impairment and Dementia: A Real-World Analysis from Germany.
Ahn N; Wawro N; Baumeister SE; Nolde M; Gerlach R; Tauscher M; Günter A; Güntner F; Rückert-Eheberg IM; Meisinger C; Linseisen J
Drugs Aging; 2023 Jul; 40(7):653-663. PubMed ID: 37178361
[TBL] [Abstract][Full Text] [Related]
7. Proton Pump Inhibitor Use and Risks of Cardiovascular Disease and Mortality in Patients With Type 2 Diabetes.
Geng T; Chen JX; Zhou YF; Lu Q; Wan Z; Liu L; Pan A; Liu G
J Clin Endocrinol Metab; 2023 May; 108(6):e216-e222. PubMed ID: 36573284
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors and myocardial infarction: an application of active comparators in a self-controlled case series.
Chui CSL; Cheung KS; Brown JP; Douglas IJ; Wong ICK; Chan EW; Wong AYS
Int J Epidemiol; 2023 Jun; 52(3):899-907. PubMed ID: 36259933
[TBL] [Abstract][Full Text] [Related]
9. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial.
Burkard T; Kaiser CA; Brunner-La Rocca H; Osswald S; Pfisterer ME; Jeger RV;
J Intern Med; 2012 Mar; 271(3):257-63. PubMed ID: 21726302
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors and the risk of cardiovascular events and cardiovascular mortality: A systematic review and meta-analysis of observational studies.
Nolde M; Ahn N; Dreischulte T; Krause E; Güntner F; Günter A; Gerlach R; Tauscher M; Amann U; Linseisen J; Meisinger C; Baumeister SE; Rückert-Eheberg IM
Eur J Intern Med; 2022 Dec; 106():80-89. PubMed ID: 36195531
[TBL] [Abstract][Full Text] [Related]
11. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.
Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):127-138. PubMed ID: 30084902
[TBL] [Abstract][Full Text] [Related]
12. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.
Simon T; Steg PG; Gilard M; Blanchard D; Bonello L; Hanssen M; Lardoux H; Coste P; Lefèvre T; Drouet E; Mulak G; Bataille V; Ferrières J; Verstuyft C; Danchin N
Circulation; 2011 Feb; 123(5):474-82. PubMed ID: 21262992
[TBL] [Abstract][Full Text] [Related]
13. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.
Charlot M; Ahlehoff O; Norgaard ML; Jørgensen CH; Sørensen R; Abildstrøm SZ; Hansen PR; Madsen JK; Køber L; Torp-Pedersen C; Gislason G
Ann Intern Med; 2010 Sep; 153(6):378-86. PubMed ID: 20855802
[TBL] [Abstract][Full Text] [Related]
14. Emulating a target trial of proton pump inhibitors and dementia risk using claims data.
Ahn N; Nolde M; Günter A; Güntner F; Gerlach R; Tauscher M; Amann U; Linseisen J; Meisinger C; Rückert-Eheberg IM; Baumeister SE
Eur J Neurol; 2022 May; 29(5):1335-1343. PubMed ID: 35170158
[TBL] [Abstract][Full Text] [Related]
15. Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis.
Malhotra K; Katsanos AH; Bilal M; Ishfaq MF; Goyal N; Tsivgoulis G
Stroke; 2018 Feb; 49(2):312-318. PubMed ID: 29339434
[TBL] [Abstract][Full Text] [Related]
16. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Leonard CE; Bilker WB; Brensinger CM; Flockhart DA; Freeman CP; Kasner SE; Kimmel SE; Hennessy S
Stroke; 2015 Mar; 46(3):722-31. PubMed ID: 25657176
[TBL] [Abstract][Full Text] [Related]
17. Risks of long-term use of proton pump inhibitor on ischemic vascular events: A distributed network analysis of 5 real-world observational Korean databases using a common data model.
Kim Y; Seo SI; Lee KJ; Kim J; Yoo JJ; Seo WW; Shin WG
Int J Stroke; 2023 Jun; 18(5):590-598. PubMed ID: 36190338
[TBL] [Abstract][Full Text] [Related]
18. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Goodman SG; Clare R; Pieper KS; Nicolau JC; Storey RF; Cantor WJ; Mahaffey KW; Angiolillo DJ; Husted S; Cannon CP; James SK; Kilhamn J; Steg PG; Harrington RA; Wallentin L;
Circulation; 2012 Feb; 125(8):978-86. PubMed ID: 22261200
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitors and risk for recurrent ischemic events or death in outpatients with symptomatic artery disease.
Muñoz-Torrero JFS; Zamorano J; Rico-Martín S; Rivas MD; Bacaicoa MA; Robles R; Sanchez-Bacaicoa C; Monreal M;
Atherosclerosis; 2020 Jan; 292():84-89. PubMed ID: 31785493
[TBL] [Abstract][Full Text] [Related]
20. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.
Dunn SP; Steinhubl SR; Bauer D; Charnigo RJ; Berger PB; Topol EJ
J Am Heart Assoc; 2013 Jan; 2(1):e004564. PubMed ID: 23525436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
